PubMed Health⌕ Search

Biomedical subjects

D Tinkelman

Publications and source records attributed to D Tinkelman.

23 records · Page 2Linked to original sources

The effect of diet on the efficacy onset and duration of action of procaterol hydrochloride tablets.

Procaterol hydrochloride, a new potent beta-2 agonist drug, was evaluated for effects of food absorption, onset of action, and efficacy in a single-dose non-blinded placebo controlled crossover design in 18 subjects. Three diet conditions, separated by a three to seven day washout period, were used and compared to a placebo treatment. The diets were standardized and included high fat, low fat, and a fasting condition. Spirometric determinations and vital signs were obtained at 0, 15, 30 minutes, and at one, two, four, six, eight hours post-dose to evaluate therapeutic availability since no technique for measuring serum levels of procaterol hydrochloride is currently available. Spirometry results indicated significant improvement in pulmonary function during all diet conditions except with the placebo treatment. A delay in onset of action was seen in the low fat diet and to a certain extent in the high fat diet as compared to the fasting condition. There was no effect of diet on procaterol hydrochloride's peak response or duration of action with improvement in pulmonary function demonstrated for up to eight hours. Tremor and headache were the most frequent side effects, and were mild and transient. No significant effects were noted in electrocardiograms, heart rate, or blood pressure. An elevation in serum glucose was seen in three subjects during the fasting challenge and was felt to be secondary to the beta-agonist effects of procaterol hydrochloride. Procaterol was found to be an effective drug with a delayed onset of action when administered with food, but no effect on subsequent efficacy or duration of action.

Adolescent↗

Use of a twelve-hour theophylline preparation in chronic adult asthmatics.

Twenty-one adult chronic asthmatic patients were studied while taking a 12-hour sustained-action theophylline tablet. Pulmonary function testing and serum theophylline levels were monitored for 12 weeks, including testing every two hours over one dosing interval on the final day of the study. Results indicate the preparation tested produced sustained stable theophylline levels for a full 12 hours, with pulmonary function also remaining elevated and stable during this period. There was minimal toxicity reported over the 12-week period and no evidence of tolerance.

Adolescent↗

Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis.

This multicenter, double-masked, randomized, parallel-group study compared the efficacy and safety of ketorolac tromethamine 0.5% ophthalmic solution with levocabastine 0.05% and ketorolac tromethamine vehicle in patients with seasonal allergic conjunctivitis. One drop of ketorolac, levocabastine, or vehicle was instilled in each eye four times daily for 6 weeks. In the majority of efficacy variables, ketorolac produced the greatest improvements, followed by levocabastine and vehicle. Ketorolac was significantly more effective (P < .05) than vehicle in reducing mean itching scores, palpebral hyperemia, bulbar hyperemia, and edema. Patients treated with ketorolac reported significant improvements (P < .05) in their ability to sleep and to concentrate on work, compared with those who received vehicle. No significant differences were noted among the treatment groups in safety or tolerability. Ketorolac tromethamine 0.5% ophthalmic solution instilled four times daily is effective and safe in reducing the signs and symptoms of seasonal allergic conjunctivitis.

Adolescent↗